KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although…
Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia. Treatment goals…
Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
The number of incident cases of AML in the countries under study will increase by 43%, from 58,000 to 82,000, in ten years. Of the countries considered in this analysis, the incidence of AML is…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Acute myeloid leukemia patient populations covering 171 countries…
Clarivate Epidemiology's coverage of chronic myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
DRG Epidemiology's coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…